Peter Foley - Concepedia

Author

Peter Foley

The University of Melbourne ORCID

Also Known As

A Armstrong, P Foley, P. A Foley, P. FOLEY, P. Foley, Peter A Foley, Peter A. Foley, Peter Anthony Foley, Peter Foley

298

Publications

11.6K

Citations

H-Index

104

Concepts

All Affiliations

The University of Melbourne St Vincent's Hospital Melbourne Skin and Cancer Foundation Skin Health Institute Probity Medical Research

About

Peter Foley is an author at The University of Melbourne specializing in medicine, dermatology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	20	25	3.2K
2	Engineering	5	5	284
3	Health Sciences	2	2	52
4	Law	1	1	35
5	Nursing	1	1	35

Peter Foley

Publications

9.2K

Citations

H-Index

Page 1

	Year	Citations
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial Andrew Blauvelt, Marjolein de Bruin‐Weller, Melinda Gooderham, The Lancet AllergyAtopic DermatitisAllergy MedicineModerate-to-severe Atopic DermatitisSkin Allergy	2017	1.2K
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial Kristian Reich, April W. Armstrong, Peter Foley, Journal of the American Academy of Dermatology	2017	712
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials Kenneth B. Gordon, Bruce Strober, Mark Lebwohl, The Lancet Autoimmune DiseaseMedicineClinical TrialsClinical DermatologyModerate-to-severe Plaque Psoriasis	2018	627
Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis Kim Papp, Kenneth B. Gordon, Diamant Thaçi, New England Journal of Medicine	2018	400
Incidence of non-melanocytic skin cancer treated in Australia Graham G. Giles, Robin Marks, Peter Foley BMJ	1988	358
Spontaneous remission of solar keratoses: the case for conservative management R. Marks, Peter Foley, Greg Goodman, British Journal of Dermatology	1986	322
A comparison of photodynamic therapy using topical methyl aminolevulinate (Metvix®) with single cycle cryotherapy in patients with actinic keratosis: a prospective, randomized study M Freeman, C Vinciullo, David M. Francis, Journal of Dermatological Treatment	2003	282
Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial Kenneth B. Gordon, Peter Foley, James G. Krueger, The Lancet Systemic TreatmentBimekizumab EfficacyClinical TrialsPlaque PsoriasisClinical Dermatology	2021	258
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial Bruce Strober, Diamant Thaçi, Howard Sofen, Journal of the American Academy of Dermatology	2022	254
Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study Mette Deleuran, Diamant Thaçi, Lisa A. Beck, Journal of the American Academy of Dermatology	2019	248

Page 1